Johnson & Johnson (NYSE:JNJ) Shares Sold by Arjuna Capital
Arjuna Capital decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 45.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,454 shares of the company’s stock after selling 12,821 shares during the period. Johnson & Johnson makes up approximately 1.5% of Arjuna Capital’s investment portfolio, making the stock its 19th biggest position. Arjuna Capital’s holdings in Johnson & Johnson were worth $1,875,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. Trillium Asset Management LLC raised its stake in shares of Johnson & Johnson by 30.9% during the second quarter. Trillium Asset Management LLC now owns 93,939 shares of the company’s stock valued at $11,399,000 after acquiring an additional 22,193 shares in the last quarter. Ramsay Stattman Vela & Price Inc. increased its position in shares of Johnson & Johnson by 1.1% during the second quarter. Ramsay Stattman Vela & Price Inc. now owns 69,648 shares of the company’s stock worth $8,451,000 after purchasing an additional 754 shares in the last quarter. Westchester Capital Management Inc. increased its position in shares of Johnson & Johnson by 0.6% during the second quarter. Westchester Capital Management Inc. now owns 68,113 shares of the company’s stock worth $8,265,000 after purchasing an additional 436 shares in the last quarter. Fragasso Group Inc. increased its position in shares of Johnson & Johnson by 2.6% during the second quarter. Fragasso Group Inc. now owns 20,185 shares of the company’s stock worth $2,449,000 after purchasing an additional 507 shares in the last quarter. Finally, Crossvault Capital Management LLC increased its position in shares of Johnson & Johnson by 8.9% during the second quarter. Crossvault Capital Management LLC now owns 52,943 shares of the company’s stock worth $6,424,000 after purchasing an additional 4,340 shares in the last quarter. Hedge funds and other institutional investors own 66.51% of the company’s stock.
In related news, EVP Michael E. Sneed sold 30,943 shares of Johnson & Johnson stock in a transaction on Friday, November 23rd. The shares were sold at an average price of $142.46, for a total transaction of $4,408,139.78. Following the sale, the executive vice president now directly owns 70,817 shares in the company, valued at approximately $10,088,589.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Joaquin Duato sold 40,000 shares of the firm’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $144.36, for a total transaction of $5,774,400.00. Following the transaction, the insider now directly owns 112,848 shares in the company, valued at $16,290,737.28. The disclosure for this sale can be found here. Insiders sold a total of 510,544 shares of company stock valued at $74,414,877 in the last three months. 0.22% of the stock is currently owned by corporate insiders.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.02. The firm had revenue of $20.35 billion during the quarter, compared to analysts’ expectations of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the company posted $1.90 EPS. Research analysts forecast that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be given a $0.90 dividend. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 annualized dividend and a yield of 2.48%. Johnson & Johnson’s dividend payout ratio is presently 49.32%.
A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a report on Tuesday, November 20th. HC Wainwright reissued a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Credit Suisse Group set a $149.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, October 14th. Citigroup upped their price target on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. Finally, Wells Fargo & Co reaffirmed an “outperform” rating and issued a $160.00 price target on shares of Johnson & Johnson in a report on Friday, September 14th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $143.90.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Read More: What is Compound Interest?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.